Literature DB >> 8809473

Functions of CD40 and its ligand, gp39 (CD40L).

J D Laman1, E Claassen, R J Noelle.   

Abstract

Initially, a role for the interaction between CD40, expressed on B cells, and gp39 (CD40L), expressed on activated T cells, has been defined in humoral immunity. CD40-CD40L interaction is an essential signal for B cell proliferation, expression of activation markers, immunoglobulin production, and isotype switching. CD40-CD40L interaction is also required for formation of B memory cells and germinal centers, and signaling through CD40 prevents apoptosis of germinal center B cells. Defective expression of CD40L in humans leads to an inability to produce isotypes other than IgM (hyper IgM syndrome), and to an absence of germinal centers. More recent evidence indicates an expansion of the role of the CD40-CD40L axis in cellular interactions beyond antibody formation. Induced expression of CD40 on monocytes can lead to CD40L-activated monocyte effector mechanisms. In addition, CD40-CD40L interactions are crucially involved in development of autoimmune disease in a number of animal models. CD40-CD40L interactions also impact on growth regulation of certain carcinomas. Manipulation of CD40L has also been used to develop novel strategies for long-term antigen-specific tolerization of peripheral T cells. Finally, the CD40-CD40L axis is involved in thymic selection. Following is a comprehensive overview of CD40L-CD40 interactions in physiological and pathogenic cellular responses and a discussion of the therapeutic ramifications of these interactions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8809473     DOI: 10.1615/critrevimmunol.v16.i1.40

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  41 in total

Review 1.  Ectopic lymphoid organogenesis: a fast track for autoimmunity.

Authors:  C M Weyand; P J Kurtin; J J Goronzy
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

2.  Murine AIDS requires CD154/CD40L expression by the CD4 T cells that mediate retrovirus-induced disease: Is CD4 T cell receptor ligation needed?

Authors:  Wen Li; William R Green
Journal:  Virology       Date:  2006-11-17       Impact factor: 3.616

3.  T cells are required for the peripheral phase of B-cell maturation.

Authors:  Novica M Milićević; Klaus Nohroudi; Zivana Milićević; Hans-Juergen Hedrich; Jürgen Westermann
Journal:  Immunology       Date:  2005-11       Impact factor: 7.397

4.  Monocyte infiltration and kidney allograft dysfunction during acute rejection.

Authors:  R Girlanda; D E Kleiner; Z Duan; E A S Ford; E C Wright; R B Mannon; A D Kirk
Journal:  Am J Transplant       Date:  2008-03       Impact factor: 8.086

Review 5.  The hyper-IgM (HIM) syndrome.

Authors:  N Ramesh; M Seki; L D Notarangelo; R S Geha
Journal:  Springer Semin Immunopathol       Date:  1998

6.  Immune responses against rHaa86 in cross-bred cattle.

Authors:  Binod Kumar; D D Ray; Srikant Ghosh
Journal:  J Parasit Dis       Date:  2013-07-10

7.  Direct B-cell stimulation by peripheral blood monocyte-derived dendritic cells in idiopathic thrombocytopenic purpura patients.

Authors:  Zhenhai Zhou; Xiaoyin Li; Juan Li; Chang Su; Lan Zhuang; Shaokai Luo; Ling Zhang
Journal:  J Clin Immunol       Date:  2010-07-14       Impact factor: 8.317

8.  CD40 ligation induces tissue factor expression in human vascular smooth muscle cells.

Authors:  U Schönbeck; F Mach; G K Sukhova; M Herman; P Graber; M R Kehry; P Libby
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

9.  B cells require "nurturing" by CD4 T cells during development in order to respond in chronic graft-versus-host model of systemic lupus erythematosus.

Authors:  Arpita Choudhury; Philip L Cohen; Robert A Eisenberg
Journal:  Clin Immunol       Date:  2010-04-08       Impact factor: 3.969

Review 10.  The significance and management of thrombocytopenia in antiphospholipid syndrome.

Authors:  Bahar Artim-Esen; Reyhan Diz-Küçükkaya; Murat İnanç
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.